Evidence map›Paper›PMID 39417382›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Frontoparietal network integrity supports cognitive function in pre-symptomatic frontotemporal dementia: Multimodal analysis of brain function, structure, and perfusion.

Xulin Liu, Peter Simon Jones, Maurice Pasternak, Mario Masellis, Arabella Bouzigues, Lucy L Russell, Phoebe H Foster, Eve Ferry-Bolder, John van Swieten, Lize Jiskoot and 26 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Xulin LiuDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.ORCID 0000-0002-8219-2848
Peter Simon JonesDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.
Maurice PasternakSunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.
Mario MasellisSunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Canada.
Arabella BouziguesDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
Lucy L RussellDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
Phoebe H FosterDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
Eve Ferry-BolderDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
John van SwietenDepartment of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Lize JiskootDepartment of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Harro SeelaarDepartment of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Raquel Sanchez-ValleAlzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.
Robert LaforceClinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec, Canada.
Caroline GraffKarolinska Institute, Department NVS, Centre for Alzheimer Research, Division of Neurogenetics, Stockholm, Sweden.
Daniela GalimbertiFondazione IRCCS Ospedale Policlinico, Milan, Italy.
Rik VandenbergheLaboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Alexandre de MendonçaFaculty of Medicine, University of Lisbon, Lisbon, Portugal.
Pietro TiraboschiFondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
Isabel SantanaFaculty of Medicine, University of Coimbra, Coimbra, Portugal.
Alexander GerhardDivision of Psychology Communication and Human Neuroscience, Wolfson Molecular Imaging Centre, University of Manchester, First floor, Core Technology Facility, Manchester, UK.
Johannes LevinDepartment of Neurology, Ludwig-Maximilians Universität München, Munich, Germany.
Sandro SorbiDepartment of Neurofarba, University of Florence, Firenze, Italy.
Markus OttoDepartment of Neurology, University of Ulm, Ulm, Germany.
Florence PasquierUniversity Lille, Lille, France.
Simon DucharmeDepartment of Psychiatry, McGill University Health Centre, McGill University, Montreal, Canada.
Chris ButlerNuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.
Isabelle Le BerParis Brain Institute - Institut du Cerveau - ICM, Sorbonne Université, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.
Elizabeth FingerDepartment of Clinical Neurological Sciences, University of Western Ontario, London, Canada.
Maria Carmela TartagliaTanz Centre for Research in Neurodegenerative Disease, Toronto Western Hospital, Toronto, Ontario, Canada.
Matthis SynofzikDepartment of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research & Centre of Neurology, University of Tübingen, Tübingen, Germany.
Fermin MorenoCognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain.
Barbara BorroniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Jonathan D RohrerDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
Kamen A TsvetanovDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.
James B RoweDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.
GENFI consortium

Funding

Alzheimer FoundationAlzheimer's Society 602Brain FoundationCambridge Commonwealth, European and International TrustCambridge University Centre for Frontotemporal DementiaCanadian Institute of Health Research 327387Carlos III Health Institute PI19/01637Dementia FoundationDioraphte Foundation 09-02-03-00EU Joint Programme-Neurodegenerative Disease Research 2019-02248European Reference Network for Rare Neurological DiseasesFederal Ministry of Education and ResearchFundació Marató de TV3, Spain 20143810Guarantors of Brain G101149Holt FellowshipMady Browaeys FundMRC Clinician Scientist Fellowship MR/M008525/1Munich Cluster for Systems Neurology 390857198National Institute for Health Research Cambridge Biomedical Research Centre BRC-1215-20014National Institute for Health Research Cambridge Biomedical Research Centre NIHR203312Netherlands Organization for Scientific Research HCMI 056-13-018Ontario Brain InstituteRegion Stockholm 733051042Swedish FTD Inititative-Schörling Foundationthe Medical Research Council MC_UU_00030/14the Medical Research Council MR/T033371/1Wellcome Trust 103838Wellcome Trust 220258Weston Brain Institute
6 · The paper itself

Abstract

introductionGenetic mutation carriers of frontotemporal dementia can remain cognitively well despite neurodegeneration. A better understanding of brain structural, perfusion, and functional patterns in the pre-symptomatic stage could inform accurate staging and potential mechanisms.

methodsWe included 207 pre-symptomatic genetic mutation carriers and 188 relatives without mutations. The gray matter volume, cerebral perfusion, and resting-state functional network maps were co-analyzed using linked independent component analysis (LICA). Multiple regression analysis was used to investigate the relationship of LICA components to genetic status and cognition.

resultsPre-symptomatic mutation carriers showed an age-related decrease in the left frontoparietal network integrity, while non-carriers did not. Executive functions of mutation carriers became dependent on the left frontoparietal network integrity in older age. DISCUSSION: The frontoparietal network integrity of pre-symptomatic mutation carriers showed a distinctive relationship to age and cognition compared to non-carriers, suggesting a contribution of the network integrity to brain resilience. HIGHLIGHTS: A multimodal analysis of structure, perfusion, and functional networks. The frontoparietal network integrity decreases with age in pre-symptomatic carriers only. Executive functions of pre-symptomatic carriers dissociated from non-carriers.

Indexed as

CognitionFrontotemporal DementiaMagnetic Resonance ImagingAdultAgedBrainExecutive FunctionFemaleFrontal LobeGray MatterHeterozygoteHumansMaleMiddle AgedMutationNerve Netatrophycerebral blood flowfrontotemporal dementiafunctional networkmultimodal neuroimagingpre‐symptomatic dementia

Identifiers

PMID39417382
PMCPMC11667541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.